Viral hepatitis country profiles
Global HIV, Hepatitis and Sexually Transmitted Infections Programmes
- Country
- Population: Fetching... (Fetching...)
- Current health expenditure (% of GDP): Fetching... (Fetching...)
- WHO region: Fetching...
- World Bank income level: Fetching... (FY26)
- Births: Fetching... (Fetching...)
- Infant mortality rate (0–11 months, per 1000 live births): Fetching... (Fetching...)
- Births attended by skilled health personnel: Fetching... (Fetching...)
- Population size estimate of people who inject drugs (PWID): Fetching... (Fetching...)
Epidemiology
Hepatitis B
Hepatitis C
Mortality
Hepatitis B
Hepatitis B testing and treatment (number)
Coverage of Hepatitis B testing and treatment (percentage)
Hepatitis C
Hepatitis C testing and treatment (cumulative number)
Coverage of hepatitis C testing and treatment (percentage)
Hepatitis and HIV Co-infection
Percentage of people living with HIV diagnosed and treated for chronic HCV
Percentage of people living with HIV who inject drugs, diagnosed and treated for chronic HCV
Prevention of hepatitis B and C
Prevention of hepatitis B and C
Metadata
Glossary and definitions
Overview
Population | Official population dataset extracted from World Population Prospects (WPP), UN Population Division |
|---|---|
Current health expenditure (% of GDP) | Current health expenditure (CHE) as percentage of gross domestic product (GDP) |
World Bank income level | World Bank country classification by income level for fiscal year 2026 (FY26), covering 2025–2026. |
Births | Number of live births over a given period; dataset extracted from World Population Prospects (WPP), UN Population Division |
Infant mortality rate (0–11 months, per 1000 live births | Infant mortality rate (between birth and 11 months per 1000 live births). Infant mortality rate is the probability of a child born in a specific year or period dying before reaching the age of one, if subject to age-specific mortality rates of that period. |
Births attended by skilled health personnel | Proportion of births attended by skilled health personnel (generally doctors, nurses or midwives but can refer to other health professionals providing childbirth care) is the proportion of childbirths attended by professional health personnel. |
Population size estimate of people who inject drugs (PWID) | Estimated number of people who inject drugs |
Epidemiology
| Prevalence of chronic hepatitis (HBV and HCV) among the general population |
|
|---|---|
Estimated number of persons living with chronic hepatitis (HBV and HCV) in 2022 |
|
Number of hepatitis (HBV and HCV) -infected persons diagnosed |
|
Number of people treated for chronic hepatitis (HBV and HCV) |
|
| Number of new chronic hepatitis (HBV and HCV) infections (annual) |
|
| Number of deaths caused by chronic hepatitis (HBV and HCV) | Deaths from HCC, cirrhosis and chronic liver diseases attributable to hepatitis B and C |
| Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years (%) in 2020 | Prevalence of hepatitis B surface antigen (HBsAg)-positive, adjusted for sampling design |
Testing and treatment
Hepatitis B diagnosis coverage (of all people infected) | Proportion of people with chronic hepatitis B (HBsAg positive) who have been diagnosed |
|---|---|
Hepatitis B treatment coverage (of all people infected with hepatitis B) | Chronic HBV treatment rate as percentage of total infected. Proportion of people with chronic hepatitis B currently receiving treatment of those eligible. |
Hepatitis B treatment coverage (of all people diagnosed with hepatitis B) | Chronic HBV treatment rate as percentage of diagnosed. Percentage of people diagnosed with chronic hepatitis B initiating treatment among those eligible. |
Hepatitis C diagnosis coverage to end of 2022 | Proportion of people with chronic hepatitis C who have been diagnosed (HCV RNA positive or HCV core antigen positive) including those cured |
Hepatitis C treatment coverage to end of 2022 (of all people infected with hepatitis C) | Chronic HCV treatment rate as percentage of total infected. Proportion of people with chronic hepatitis C initiating treatment. |
Hepatitis and HIV co-infection
People living with HIV who were tested for and diagnosed with chronic hepatitis C infection (HCV) | Percentage of people living with HIV on antiretroviral therapy who have been diagnosed with chronic HCV infection (positive HCV RNA (PCR) or HCV core antigen) by the end of the reporting period. |
|---|---|
People living with HIV treated for chronic hepatitis C infection (HCV) | Percentage of people living with HIV on antiretroviral therapy diagnosed with chronic HCV infection who have initiated HCV treatment by the end of the reporting period. |
People living with HIV and who inject drugs who were tested for and diagnosed with chronic hepatitis C infection (HCV) | Percentage of people living with HIV, who inject drugs, and on antiretroviral therapy who have been diagnosed with chronic HCV infection (positive HCV RNA (PCR) or HCV core antigen) by the end of the reporting period. |
People living with HIV and who inject drugs treated for chronic hepatitis C infection (HCV) | Percentage of people living with HIV, who inject drugs, and on antiretroviral therapy diagnosed with chronic HCV infection who have initiated HCV treatment by the end of the reporting period. |
Prevention of hepatitis B and C
Harm reduction: NSP coverage among PWID per year | Number of needles and syringes distributed per person who injects drugs per year by needle–syringe programmes |
|---|---|
Harm reduction: Coverage of opioid agonist maintenance therapy among people who inject drugs | Percentage of people who inject drugs receiving opioid agonist maintenance therapy |
Copyright and licensing
| Copyright | Attribution 4.0 International (CC BY 4.0) |
|---|---|
| License | The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies. Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you. You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion. Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition: Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final. |
| Permission type | Publicly accessible |
| Prohibited uses | You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content. You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services. |
| Citation | World Health Organization 2025 data.who.int, Viral hepatitis country profiles > Epidemiology [Dashboard]. https://data.who.int/dashboards/hepatitis/epidemiology |
| Disclaimer | WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you. Maps All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use. For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions. |